Expression Changes Confirm Genomic Variants Predicted to Result in Allele-Specific, Alternative mRNA Splicing by Rogan, Peter
Western University 
Scholarship@Western 
Biochemistry Publications Biochemistry Department 
3-5-2020 
Expression Changes Confirm Genomic Variants Predicted to 
Result in Allele-Specific, Alternative mRNA Splicing 
Peter Rogan 
The University of Western Ontario, progan@uwo.ca 
Follow this and additional works at: https://ir.lib.uwo.ca/biochempub 
 Part of the Biochemistry Commons 
Citation of this paper: 
Rogan, Peter, "Expression Changes Confirm Genomic Variants Predicted to Result in Allele-Specific, 
Alternative mRNA Splicing" (2020). Biochemistry Publications. 195. 
https://ir.lib.uwo.ca/biochempub/195 
Expression Changes Confirm
Genomic Variants Predicted to Result
in Allele-Specific, Alternative mRNA
Splicing
Eliseos J. Mucaki1, Ben C. Shirley2 and Peter K. Rogan1,2,3,4*
1 Department of Biochemistry, University of Western Ontario, London, ON, Canada, 2 CytoGnomix, London, ON, Canada,
3 Department of Oncology University of Western Ontario, London, ON, Canada, 4 Department of Computer Science,
University of Western Ontario, London, ON, Canada
Splice isoform structure and abundance can be affected by either noncoding or
masquerading coding variants that alter the structure or abundance of transcripts.
When these variants are common in the population, these nonconstitutive transcripts
are sufficiently frequent so as to resemble naturally occurring, alternative mRNA splicing.
Prediction of the effects of such variants has been shown to be accurate using information
theory-based methods. Single nucleotide polymorphisms (SNPs) predicted to significantly
alter natural and/or cryptic splice site strength were shown to affect gene expression.
Splicing changes for known SNP genotypes were confirmed in HapMap lymphoblastoid
cell lines with gene expression microarrays and custom designed q-RT-PCR or TaqMan
assays. The majority of these SNPs (15 of 22) as well as an independent set of 24 variants
were then subjected to RNAseq analysis using the ValidSpliceMut web beacon (http://
validsplicemut.cytognomix.com), which is based on data from the Cancer Genome Atlas
and International Cancer Genome Consortium. SNPs from different genes analyzed with
gene expression microarray and q-RT-PCR exhibited significant changes in affected
splice site use. Thirteen SNPs directly affected exon inclusion and 10 altered cryptic site
use. Homozygous SNP genotypes resulting in stronger splice sites exhibited higher levels
of processed mRNA than alleles associated with weaker sites. Four SNPs exhibited
variable expression among individuals with the same genotypes, masking statistically
significant expression differences between alleles. Genome-wide information theory and
expression analyses (RNAseq) in tumor exomes and genomes confirmed splicing effects
for 7 of the HapMap SNP and 14 SNPs identified from tumor genomes. q-RT-PCR
resolved rare splice isoforms with read abundance too low for statistical significance in
ValidSpliceMut. Nevertheless, the web-beacon provides evidence of unanticipated
splicing outcomes, for example, intron retention due to compromised recognition of
constitutive splice sites. Thus, ValidSpliceMut and q-RT-PCR represent complementary
resources for identification of allele-specific, alternative splicing.
Keywords: allele-specific gene expression, mRNA splicing, single nucleotide polymorphism, mutation, cryptic
splicing, intron retention, alternative splicing, information theory
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INTRODUCTION
Accurate and comprehensive methods are needed for
predicting impact of noncoding mutations, in particular,
mRNA splicing defects, which are prevalent in genetic
disease (Krawczak et al., 1992; Teraoka et al., 1999; Ars
et al., 2003; Spielmann and Mundlos, 2016; Gloss and
Dinger, 2018). This class of mutations may account for as
much as 62% of point mutations (López-Bigas et al., 2005).
Large transcriptome studies have suggested that a large
fraction of genome-wide association studies (GWAS) signals
for disease and complex traits are due to single nucleotide
polymorphisms (SNPs) affecting mRNA splicing (Park et al.,
2018). ValidSpliceMut (Shirley et al., 2019) presents evidence
of altered splicing (Viner et al., 2014; Dorman et al., 2014) for
309,848 validated genome splice-variant predictions (Shirley
et al., 2013). The majority of mutations were associated with
exon skipping, cryptic site use, or intron retention, and in
these cases ValidSpliceMut assigns a molecular phenotype
classification to all variants as either aberrant, likely aberrant
or inducing alternative isoforms.
While allele-specific alternative splicing can predispose for
disease susceptibility (Park et al., 2018), these genetic variations
also are associated with common phenotypic variability in
populations (Hull et al., 2007). Soemedi et al. (2017) determined
that 10% of a set of published disease-causing exonic mutations
(N = 4,964) altered splicing. Their analysis of a control set of exonic
SNPs common among those without disease phenotypes revealed a
smaller proportion (3%) that altered splicing (N = 228). However,
we recently showed that splice-altering, common SNPs are
considerably more abundant in tumor genomes in the
ValidSpliceMut web-beacon (http://validsplicemut.cytognomix.
com; Shirley et al., 2019). Variants with higher germline
population frequencies which impact splicing are less likely than
rare mutations with direct splicing effects to be involved in
Mendelian diseases or cancer. The present study analyzes
predicted splice-altering polymorphic variants in genotyped
lymphoblastoid cell lines by q-RT-PCR, expression microarrays of
samples of known SNP genotypes, and high throughput expression
data corresponding to sequenced tumor exomes and genomes. The
relatively high frequencies of these variants enable comparisons of
expressed transcripts in multiple individuals and genotypes. Effects
of these SNPs are confirmed by multiple methods, although the
supporting evidence from these distinct approaches is often
complementary, rather than entirely concordant.
An estimated 90% to 95% of all multiexon genes are
alternatively spliced (Pan et al., 2008; Wang et al., 2008; Baralle
and Giudice, 2017). The selection of splicing signals involves
exon and intron sequences, complementarity with snRNAs,
RNA secondary structure, and competition between
spliceosomal recognition sites (Moore and Sharp, 1993; Berget,
1995; Park et al., 2018). U1 snRNP interacts with the donor (or
5') splice site (Zhuang and Weiner, 1986; Séraphin et al., 1988)
and U2 (and U6) snRNP with the acceptor and branch sites of
pre-mRNA (Parker et al., 1987; Wu and Manley, 1989). The
majority of human splice donors (5') and acceptors (3') base pair
with the U1 and U2 RNAs in spliceosomes, but are generally not
precisely complementary to these sequences (Rogan et al., 2003).
Additional exonic and intronic cis-regulatory elements can
promote or suppress splice site recognition through
recruitment of trans-acting splicing factors. SR proteins are
positive trans-acting splicing factors which contain RNA-
recognition motifs (RRM) and a carboxy-terminal domain
enriched in Arg/Ser dipeptides (SR domain; Birney et al.,
1993). Binding of RRMs in pre-mRNA enhances exon
recognition by promoting interactions with spliceosomal and
other proteins (Fu and Maniatis, 1992). SR proteins function in
splice site communication by forming an intron bridge needed
for exon recognition (Zuo and Maniatis, 1996). Factors that
negatively impact splicing include heterogeneous nuclear
ribonucleoproteins (hnRNPs; Martinez-Contreras et al., 2007).
Splicingmutations affect normal exon recognition by altering the
strengths of natural donor or acceptor sites and proximate cryptic
sites, either independently or simultaneously. Weakened splice sites
reduce of kinetics of mRNA processing, leading to an overall
decrease in full length transcripts, increased exon skipping, cryptic
splice site activation within exons or within adjacent introns, intron
retention, and inclusion of cryptic, pseudo-exons (Talerico and
Berget, 1990; Carothers et al., 1993; Buratti et al., 2006; Park et al.,
2018). The kinetics of splicing at weaker cryptic sites is also slower
than at natural sites (Domenjoud et al., 1993). Mutations strengthen
cryptic sites either by increasing resemblance to “consensus
sequences” (Nelson and Green, 1990) or by modulating the levels
of SR proteins contributing to splice site recognition (Mayeda and
Krainer, 1992; Cáceres et al., 1994). Mutations affecting splicing
regulatory elements (Dietz et al., 1993; Richard and Beckmann,
1995) disrupt trans-acting SR protein interactions (Staknis and
Reed, 1994) with distinct exonic and intronic cis-regulatory
elements (Black, 2003).
Information theory-based (IT-based) models of donor and
acceptor mRNA splice sites reveal the effects of changes in
strengths of individual sites (termed Ri; Rogan et al., 1998;
Rogan et al., 2003). This facilitates prediction of phenotypic
severity (Rogan and Schneider, 1995; von Kodolitsch et al., 1999;
von Kodolitsch et al., 2006). The effects of splicing mutations can
be predicted in silico by information theory (Rogan and
Schneider, 1995; Kannabiran et al., 1998; Rogan et al., 1998;
Svojanovsky et al., 2000; Rogan et al., 2003; Caminsky et al., 2014;
Dorman et al., 2014; Viner et al., 2014; Caminsky et al., 2016;
Mucaki et al., 2016; Shirley et al., 2019), and these predictions can
be confirmed by in vitro experimental studies (Vockley et al.,
2000; Lamba et al., 2003; Rogan et al., 2003; Khan et al., 2004;
Susani et al., 2004; Hobson et al., 2006; Caux-Moncoutier et al.,
2009; Olsen et al., 2014; Vemula et al., 2014; Peterlongo et al.,
2015). Strengths of one or more splice sites may be altered and, in
some instances, concomitant with amino acid changes in coding
sequences (Rogan et al., 1998; Peterlongo et al., 2015). Information
analysis has been a successful approach for recognizing
nondeleterious, sometimes polymorphic variants (Rogan and
Schneider, 1995; Colombo et al., 2013), and for distinguishing of
milder from severe mutations (Rogan et al., 1998; von Kodolitsch
et al., 1999; Lacroix et al., 2012).
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Predicting the relative abundance of various transcripts by
information analysis requires integration of the contributions of
all pertinent cis-acting regulatory elements. We have applied
quantitative methods to prioritize inferences as to which SNPs
impact gene expression levels and transcript structure. Effects of
mutations on combinations of splicing signals reveal changes in
isoform structure and abundance (Mucaki et al., 2013; Caminsky
et al., 2014). Multisite information theory-based models have
also been used to detect and analyze SNP effects on cis-acting
promoter modules that contribute to establishing transcript
levels (Bi and Rogan, 2004; Vyhlidal et al., 2004; Lu et al.,
2017; Lu and Rogan, 2019).
The robustness of this approach for predicting rare,
deleterious splicing mutations justifies efforts to identify
common SNPs that impact mRNA splicing. We previously
described SNPs from dbSNP that affect splicing (Rogan et al.,
1998; Nalla and Rogan, 2005). Here, we explicitly predict and
validate SNPs that influence mRNA structure and levels of
expression of the genes containing them in immortalized
lymphoblastoid cell lines and tumors. Since constitutive
splicing mutations can arise at other locations within pre-
mRNA sequences that elicit cryptic splicing, we examined
whether more common genomic polymorphisms might
frequently affect the abundance and structure of splice isoforms.
METHODS
Information Analysis
The protein-nucleic acid interactions intrinsic to splicing can be
analyzed using information theory, which comprehensively and
quantitatively models functional sequence variation based on a
thermodynamic framework (Schneider, 1997). Donor and
acceptor splice site strength can be predicted by the use of IT-
based weight matrices derived from known functional sites
(Rogan et al., 2003). The Automated Splice Site and Exon
Definition server (ASSEDA) is an online resource based on the
hg19 coordinate system to determine splice site information
changes associated with genetic diseases (Mucaki et al., 2013).
ASSEDA is now part of the MutationForecaster (http://www.
mutationforecaster.com) variant interpretation system.
Creation of Exon Array Database
Exon-level microarrays have been used to compare abnormal
expression for different cellular states, which can then be
confirmed by q-RT-PCR (Thorsen et al., 2008). We
hypothesized that the predicted effect of SNPs on expression of
the proximate exon would correspond to the expression of exon
microarray probes of genotyped individuals in the HapMap
cohort. We used the dose-dependent expression of the minor
allele to qualify SNPs for subsequent information analysis
consistent with alterations of mRNA splicing. Additional SNPs
predicted by information analysis were also tested for effects on
splicing (Nalla and Rogan, 2005).
Expression data were normalized using the PLIER (Probe
Logarithmic Intensity Error) method on Affymetrix Human
Exon 1.0 ST microarray data for 176 genotyped HapMap cell
lines (Huang et al., 2007, Gene Expression Omnibus accession
no. GSE 7792; Nembaware et al., 2008). Microarray probes which
overlap SNPs, that were subsequently removed, were identified
by intersecting dbSNP129 with probe coordinates [obtained
from X:MAP (Yates et al., 2008) using the Galaxy Browser
(Giardine et al., 2005)]. A MySQL database containing the
PLIER normalized intensities and CEU (Utah residents with
Northern and Western European ancestry) and YRI (Yoruba in
Ibadan) genotypes for Phase I+II HapMap SNPs was created.
Tables were derived to link SNPs to their nearest like-stranded
probeset (to within 500 nt), and to associate probesets to the
exons they may overlap (transcript and exon tables from
Ensembl version 51). A MySQL query was used to create a
table containing the splicing index (SI; intensity of a probeset
divided by the overall gene intensity) of each probeset for each
HapMap individual.
The database was queried to identify significant SI changes of
an exonic probeset based on the genotype of a SNP the probeset
was associated with (SNP within natural donor/acceptor region
of exon). Probesets displaying a stepwise change in mean SI
(where the mean SI of the heterozygous group is in between the
mean SI values of the two homozygous groups) were identified
using a different program script (criteria: the mean SI of
homozygous rare and heterozygous groups are < 90% of the
homozygous common group). Splicing Index boxplots were
created with R, where the x- and y-axis are genotype and SI,
respectively (Supplementary Image 1). These boxplots analyze
the effect a SNP has on a particular probeset across
all individuals.
SNPs with effects on splicing were validated by q-RT-PCR of
lymphoblastoid cell lines. Where available, results were also
compared to abnormal splicing patterns present in RNAseq
data from tumors carrying these same SNPs (in the
ValidSpliceMut database; Shirley et al., 2019). SNPs predicted
to exhibit nominal effects on splicing (DRi < 1 bit) were included
to determine minimal detectable changes by q-RT-PCR.
Cell Culture and RNA Extraction
EBV-transformed lymphoblastoid cell lines of HapMap
individuals with our SNPs of interest (homozygous common,
heterozygous and homozygous rare when available) were
ordered from the Coriell Cell Repositories (CEU: GM07000,
GM07019, GM07022, GM07056, GM11992, GM11994,
GM11995, GM12872; YRI: GM18855, GM18858, GM18859,
GM18860, GM19092, GM19093, GM19094, GM19140,
GM19159). Cells were grown in HyClone RPMI-1640 medium
[15% FBS (HyClone), 1% L-Glutamine, and 1% Penicillin:
streptomycin (Invitrogen); 37°C, 5% CO2]. RNA was extracted
with Trizol LS (Invitrogen) from 106 cells and treated with
DNAase [20 mM MgCl2 (Invitrogen), 2 mM DTT (Sigma-
Aldrich), 0.4 U/mL RNasin (Promega), 10 µg/ml DNase
(Worthington Biochemical) in 1x TE buffer] at 37°C for 15
min. The reaction was stopped with EDTA (0.05 M; 2.5% v/v),
and heated to 65°C for 20 min, followed by ethanol precipitation
(resuspended in 0.1% v/v DEPC-treated 1x TE buffer). DNA was
extracted using a Puregene Tissue Core Kit B (Qiagen).
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Design of Real-Time Expression Assays
Sequences were obtained from UCSC and Ensembl. DNA
primers used to amplify a known splice form, or one predicted
by information analysis, were designed using Primer Express
(ABI). DNA primers (Supplementary Table 1) were obtained
from IDT (Coralville, IA, USA), and dissolved to 200 uM.
Primers were placed over junctions of interest to amplify a
single splice form. Tm ranged from 58°C–65°C, and amplicon
lengths varied from 69–136 nt. BLASTn (Refseq_RNA database)
was used to reduce possible cross-hybridization. Primers were
designed to amplify the wildtype splice form, exon skipping (if a
natural site is weakened), and cryptic site splice forms which
were either previously reported (UCSC mRNA and EST tracks)
or predicted by information analysis (where Ri cryptic site ≥ Ri
weakened natural site).
Two types of reference amplicons were used to quantify allele
specific splice forms. These consisted of intrinsic products
derived from constitutively spliced exons with the same gene
and external genes with high uniformity of expression among
HapMap cell lines. Reference primers internal to the genes of
interest were designed 1–4 exons adjacent from the affected exon
(exons without any evidence of variation in the UCSC Genome
Browser; Kent et al., 2002), placed upstream of the SNP of
interest whenever possible. Two advantages to including an
internal reference in the q-RT-PCR experiment include:
potential detection of changes in total mRNA levels; and
account for inter-individual variation of expression.
External reference genes (excluding the SNP of interest) were
chosen based on consistent PLIER intensities with low
coefficients of variation in expression among all 176 HapMap
individuals. The following external controls were selected: exon
39 of SI (PLIER intensity 11.4 ± 1.7), exon 9 of FRMPD1 (22 ±
2.81), exon 46 of DNAH1 (78.5 ± 9.54), exon 3 of CCDC137
(224 ± 25), and exon 25 of VPS39 (497 ± 76). The external
reference chosen for an experiment was matched to the intensity
of the probeset within the exon of interest. This decreased
potential errors in DDCT values and proved to be accurate and
reproducible for most genes.
To control for interindividual variation in expression, we
compared expression in HapMap individuals based on their SNP
genotypes and familial relatedness. Families with all three possible
genotypes were available (homozygous common, rare, and
heterozygous) for 12 of these SNPs (rs1805377, rs2243187,
rs2070573, rs2835655, rs2835585, rs2072049, rs1893592,
rs6003906, rs1018448, rs13076750, rs16802, and rs8130564). For
those families in which all genotypes were not represented, samples
from the same ethnic background (YRI or CEU populations) were
compared for the missing genotype (N = 8; rs17002806, rs2266988,
rs1333973, rs743920, rs2285141, rs2838010, rs10190751,
rs16994182; individuals with homozygous common and rare
genotypes were from the same families for the latter two SNPs).
Two SNPs were tested using homozygous individuals from
different ethnic backgrounds: rs3747107 (GUSBP11) and
rs2252576 (BACE2). While the splicing impact of rs3747107 was
clearly observable by q-RT-PCR, either background or data noise
did impact the interpretation of effects of rs2252576.
PCR and Quantitative RT-PCR
M-MLV reverse transcriptase (Invitrogen) converted 1µg of
DNase-treated RNA to cDNA with 20 nt Oligo-dT (25µg/ml;
IDT) and rRNAsin (Promega). Precipitated cDNA was
resuspended in water at 20 ng/µl of original RNA
concentration. All designed primer sets were tested with
conventional PCR to ensure a single product at the expected
size. PCR reactions were prepared with 1.0 M Betaine (Sigma-
Aldrich), and were heated to 80°C before adding Taq Polymerase
(Invitrogen). Optimal Tm for each primer set was determined to
obtain maximum yield.
Quantitative PCR was performed with an Eppendorf
Mastercycler ep Realplex 4, a Bio-Rad CFX96, as well as a
Stratagene Mx3005P. SYBR Green assays were performed
using the KAPA SYBR FAST qPCR kit (Kapa Biosystems) in
10 µl reactions using 200 µM of each primer and 24 ng total of
cDNA per reaction. For some tests, SsoFast EvaGreen supermix
(Bio-Rad) was used with 500 µM of each primer instead.
When testing the effect of a SNP, amplification reactions with
all primers designed to detect all relevant isoforms (as well as the
gene internal reference and external reference) were run
simultaneously, in triplicate. Ct values obtained from these
experiments were normalized against the same external
reference using the Relative Expression Software Tool (REST;
http://www.gene-quantification.de/rest.html; Pfaffl et al., 2002).
Taqman Assay
Two dual-labeled Taqman probes were designed to detect the
two splice forms of XRCC4 (detecting alternative forms of exon 8
either with or without a 6 nt deletion at the 5' end). Probes were
placed over the sequence junction of interest where variation
would be near the probe middle (Supplementary Table 1). The
assay was performed on an ABI StepOne Real-Time PCR system
using ABI Genotyping Master Mix. Experiment was run in 25 µl
reactions (300 nM each primer, 400nM probe [5'-FAM or TET
fluorophore with a 3' Black Hole quencher; IDT], and 80 ng
cDNA total). Probes were tested in separate reactions.
RNAseq Analyses
The previous analyses were extended to include 24 additional,
common SNPs for their potential influence on splicing. All SNVs
present in ICGC (International Cancer Genome Consortium)
patients (Shirley et al., 2019) were evaluated by the Shannon
Pipeline (SP; Shirley et al., 2013) to identify those altering splice
site strength. Common SNPs (average heterozygosity > 10% in
dbSNP 150) predicted to decrease natural splice site strength by
SP (where DRi < −1 bit) were selected. ICGC patients carrying
these flagged SNPs were identified, and the expression of the
corresponding SNP-containing region in RNAseq was visualized
with IGV (Integrated Genome Viewer; https://igv.org; Robinson
et al., 2017). Similar RNAseq reads were grouped using IGV
collapse and sort commands, which caused nonconstitutive
spliced reads to cosegregate to the top of the viewing window.
IGV images which did not meet our gene expression criteria
(exon affected by the SNP must have ≥5 RNAseq reads present)
were eliminated. As this generated thousands of images, we
Mucaki et al. Confirming Predicted Allele-Specific mRNA Splicing
Frontiers in Genetics | www.frontiersin.org March 2020 | Volume 11 | Article 1094
report the analysis of two ICGC patients [DO47132 (Renal Cell
Cancer) and DO52711 (Chronic Lymphocytic Leukemia)],
chosen randomly, preselecting tissues to increase the likelihood
of finding expression in these regions. Images were evaluated
sequentially (in order of rsID value) and only concluded once the
first 24 SNPs meeting these criteria were found. This type of
analysis could not reveal a splicing event to be more abundant in
these patients when compared to noncarriers. Nevertheless,
spl ic ing information changes result ing from SNPs
corresponded to observed alternative and/or other novel splice
isoforms. We then queried the ValidSpliceMut database for these
SNPs, as abnormal splicing was only flagged in the database
when the junction-read or read-abundance counts significantly
exceeded corresponding evidence type in a large set of normal
control samples (Shirley et al., 2019).
RESULTS
Selection of Candidate SNPs Affecting
Splicing
A publicly available exon microarray dataset was initially used to
locate exons affected by SNPs altering splice site strength. A
change in the mean SI of a diagnostic probeset in individuals of
differing genotypes at the same variant can suggest altered
splicing. The increase or decrease in SI is related to the
expected impact of the SNP on splicing. For example, an
exonic probe which detects a normally spliced mRNA will
have decreased SI in the event of skipping. Mean SI may be
increased when a probe detects the use of an intronic cryptic
splice site. SNPs with strong impact on splicing will distinguish
mean SI levels of individuals homozygous for the major versus
minor alleles (and with heterozygous genotypes).
There were 9,328 HapMap-annotated SNPs within donor/
acceptor regions of known exons which contained at least one
probeset. Of 987 SNPs that are associated to exonic probesets
which differ in mean SI between the homozygous common and
rare HapMap individuals, 573 caused a decrease in natural site Ri
value. Inactivating and leaky splicing variants (reduction in
information content where final Ri ≥ Ri,minimum [minimum
functional splice site strength]) both exhibit reduced SI values
and were similarly abundant. Thus, both severe and moderate
splicing mutations with reduced penetrance and milder
molecular phenotypes were detected, consistent with
Mendelian disorders (von Kodolitsch et al., 1999; von
Kodolitsch et al., 2006).
Of the SNPs associated with significant changes in Ri (termed
DRi), 9,328 occurred within the natural splice sites of exons
detectable with microarray probesets. We initially focused on 21
SNPs on chromosome 21 (0.23% total, 18.8% of chr21) and 34 on
chromosome 22 (0.36% of total, 14.5% of chr22) associated with
stepwise decreases in probeset intensity at each genotype. Seven
of the chr21 SNPs and nine of the chr22 SNPs caused
information changes with either natural splice site DRi ≥ 0.1
bits, or cryptic site(s) with an Ri value comparable to a
neighbouring natural site, and in which mRNA or EST data
supported use of the cryptic site. These SNPs included:
rs2075276 [MGC16703], rs2838010 [FAM3B], rs3747107
[GUSBP11], rs2070573 [C21orf2], rs17002806 [WBP2NL],
rs3950176 [EMID1], rs1018448 [ARFGAP3], rs6003906
[DERL3], rs2266988 [PRAME], rs2072049 [PRAME],
rs2285141 [CYB5R3], rs2252576 [BACE2], rs16802 [BCR],
rs17357592 [COL6A2] , rs16994182 [CLDN14] , and
rs8130564 [TMPRSS3].
The minimum information change for detecting a splicing
effect by expression microarray is constrained by several factors.
Detection of splice isoforms can be limited by genomic probeset
coverage, which cannot distinguish alternative splicing events in
close proximity (see Figure 1A). Even where genotype-directed
SI changes are very distinct, some individuals with the common
allele have equivalent SI values to individuals with the rare allele
[rs2070573 (Figure 2) and rs1333973 (Figure 3)]. In some cases,
the number of individuals with a particular genotype is
insuffic ient for s ta t is t ica l s ignificance (rs2243187;
Supplementary Image 1.4). Although exon microarrays can be
used to find potential alternate splicing and give support to our
predictions, it became necessary to validate the microarray
predictions by q-RT-PCR, TaqMan assays, and with RNAseq
data from SNP carriers.
We report q-RT-PCR validation studies for 13 of the 16 SNPs
(q-RT-PCR primers could not be designed for rs16994182,
rs2075276, and rs3950176), along with nine other candidate
SNPs from our previous information theory-based analyses
(Nalla and Rogan, 2005): rs1805377 [XRCC4], rs2243187
[IL19], rs2835585 [TTC3], rs2865655 [TTC3], rs1893592
[UBASH3A], rs743920 [EMID1], rs13076750 [LPP], rs1333973
[IFI44L], and rs10190751 [CFLAR].
After amplification of known and predicted splice forms
(Supplementary Table 1), 15 SNPs showed measurable
changes in splicing consistent with information-theory
predictions. Ten increase alternate splice site use (two of which
increased strength of cryptic site, eight activated an unaffected
pre-existing cryptic site), six affect exon inclusion (five increased
exon skipping), three increased activation of an alternative exon,
and four decreased overall expression levels. Altered splicing
could not be validated for six SNPs, however experimental
analyses of three of the five SNPs where DRi < 1 bit were
hampered by high interindividual variability in expression.
Changes in splice site information were used to predict
observed differences in splice isoform levels (Table 1).
Figures 1–3 and Supplementary Image 1 indicate the
experimentally-determined splicing effects for each SNP, a
modified UCSC Genome Browser image of the relevant region,
boxplots showing exon microarray expression levels of each
allele for the relevant probesets, and an IGV image of the
RNAseq results for an individual tumor carrying the SNP.
Abundance of the aberrant splice forms measured by q-RT-
PCR (relative to an internal gene reference) is indicated in
Table 2. Changes in predicted splice site strength were
consistent with results measured by q-RT-PCR for 12 out of
the 15 SNP (exceptions were rs2070573, rs17002806, and
rs2835585). Variants predicted to reduce strength ≥ 100-fold
Mucaki et al. Confirming Predicted Allele-Specific mRNA Splicing
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FIGURE 2 | Splicing Impact of rs2070573 (C21orf2). (A) The single nucleotide polymorphisms (SNP) rs2070573 is a common polymorphism which alters the first
nucleotide of the extended form of C21orf2 exon 6. (B) The donor site is strengthened by the presence of the C-allele (Ri 0.4 to 4.0 bits; A > C) and its use extends
the exon by 360 nt. Q-RT-PCR found a ~4-9-fold and ~17-23-fold increase in the extended exon 6 splice form in the A/C and C/C cell lines tested, respectively.
(C) The exon microarray probeset which detects the extension (ID 3934488) shows a stepwise increase in SI with C-allele individuals which supports the q-RT-PCR
result. (D) The variant was present in ValidSpliceMut, which associated the A-allele with an increase in total intron retention [six patients flagged for total intron
retention read abundance; p=0.019 (average over all patients)]. This image displays sequence read distributions in the RNAseq data of TCGA BRCA patient, TCGA-
BH-A0H0, who is heterozygous for rs2070573. The IGV panel indicates reads corresponding to total intron 6 retention [Box 1] and which extend beyond the
constitutive donor splice site of exon 6 into the adjacent intron [Box 2]. All 4 reads which extend over the exon splice junction are derived from the G-allele (strong
binding site; not all visible in panel D).
FIGURE 1 | Splicing Impact of rs1805377 (XRCC4). The natural acceptor of XRCC4 exon 8 is abolished by rs1805377 (11.5 −> 0.6 bits) while simultaneously
strengthening a second exonic cryptic acceptor 6nt downstream (11.4 to 11.8 bits), resulting in a 6nt deletion in the mRNA. (A) Both of these acceptor sites have
been validated in GenBank mRNAs, i.e., NM_022406 and NM_003401 (UCSC panel derived from http://genome.ucsc.edu). (B) The relative abundance of the two
splice forms was determined by q-RT-PCR. The weaker rs1805377 A/A genotype (0.6 bit acceptor) was used ~47-fold less frequently than the cryptic downstream
acceptor (11.8 bits). (C) The two splice isoforms cannot be distinguished by the exon microarray as the upstream probeset (ID 2818500) does not overlap the
variable region, though the average expression of the rs1805377 A/A genotype is reduced. (D) ValidSpliceMut flagged this mutation for intron retention, which can
be observed in the RNAseq of heterozygous ICGC patient DO27779 [Box 1]. Use of both acceptor sites is also evident [Box 2]. For more detail for this and all of the
other single nucleotide polymorphisms (SNPs) analyzed, refer to Supplementary Image 1.
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were found to reduce expression by 38- to 58-fold, the variance
falling within the margin of measurement error. Modest natural
splice site affinity changes predicted to be < eightfold (DRi < 3.0)
did not consistently result in detectable changes in splicing. In
some instances, lower abundance splice forms were observed (i.e.
rs2835585 altered exon skipping levels by up to 8.8-fold;
nevertheless, the normal splice form predominated).
SNPs Affecting Cryptic Site Strength and
Activity
Increased cryptic site use coinciding with a decrease in natural
site strength (Table 1) was validated for: rs1805377 (Figure 1);
rs2243187 (Supplementary Image 1.4) ; rs3747107
(Supplementary Image 1.8); rs17002806 (Supplementary
Image 1.13); rs6003906 (Supplementary Image 1.15); and
rs13076750 (Supplementary Image 1.12). rs2070573 (Figure
2) and rs743920 (Supplementary Image 1.7) strengthened
cryptic splice sites resulting in increased use of these sites.
Despite the difference in strength between the natural and
cryptic sites affected by rs743920, the upstream 2.4 bit site was
used more frequently (Table 2). Both IL19 and XRCC4 regions
tested showed preference to the upstream acceptor as well, which
is consistent with the processive mechanism documented to
recognize acceptor splice sites (Robberson et al., 1990).
SNPs Affecting Exon Inclusion
SNPs that reduced natural site strength (DRi from 1.6 to 10.9
bits) increased exon skipping from 2- to 27-fold for homozygotes
of differing genotypes of rs2835585 (Supplementary Image
1.21), rs1018448 (Supplementary Image 1.3), rs1333973
(Figure 3), rs2266988 (Supplementary Image 1.9), and
rs13076750 (Supplementary Image 1.12). The exon
microarray probesets for rs1018448 and rs1333973 detect
decreased expression by genotype, which is consistent with
increased exon skipping. Changes of average SI values did not
correspond as well to specific genotypes for rs2835585 (TTC3),
rs2266988 (PRAME), and rs13076750 (LPP), possibly due to
increased cryptic site use (LPP) or large differences in the
abundance o f cons t i tu t i ve and sk ipped i so forms
(PRAME, TTC3).
SNPs Promoting Alternate Exon Use
SNP-related decreases in natural splice site strength may
promote the use of alternative exons up or downstream of the
affected exon. rs10190751 (Supplementary Image 1.2) is known
to modulate the presence of the shorter c-FLIP(S) splice form of
CFLAR (Ueffing et al., 2009). The use of this exon differed by 217-
fold between the strong and weak homozygotes tested, which was
reflected by the expression microarray result. By q-RT-PCR, the
CFLAR (L) form using an alternate downstream exon was found
to be 2.1-fold more abundant in the homozygote with the weaker
splice site. rs3747107 (Supplementary Image 1.8) and
rs2285141 (Supplementary Image 1.20) exhibit evidence of an
increased preference by q-RT-PCR for activation of an alternate
exon, though the microarray results for the corresponding
genotypes for both SNPs were not significantly different.
FIGURE 3 | Splicing Impact of rs1333973 (IFI44L). (A) The natural donor of IFI44L exon 2 is weakened from 9.1 to 4.6 bits (A > T) by rs1333973, increasing the
frequency of exon 2 skipping and other events. (B) By q-RT-PCR, skipping was found to be 15.6-fold higher while normal splicing was 15.4-fold lower in A
homozygotes (relative to T homozygotes). (C) Exon microarray data strongly supports the q-RT-PCR findings. (D) ICGC patient DO6354 is homozygous for the
T-allele, which resulted in exon 2 skipping [Box 3], failure to recognize the exon 2 donor causing total retention of intron 2 [Box 1], and activation of an upstream
exonic 2.4 bit cryptic donor 375 nt from the affected site [Box 2].
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TABLE 1 | Summary of q-RT-PCR results.
Summary of q-RT-PCR results SNP effects (Increase/Decrease in fold change of
homozygotes)
Additional Expression
Evidence
Gene Supplementary Image 1 panel /
rsID / HGVS notation
Splice
type
Information Change
(n–natural, c–cryptic site)
Fold
change
Natural
site
Cryptic
site
Exon
skipping
Alternate
exon
Total
mRNA
In-framea Exon
microarray
RNAseq
(Valid-SpliceMut)
XRCC4 S1.6/ rs1805377 /
NM_003401: c.894-7G>A
NM_022406: c.894-1G>A
A 11.5 (G) -> 0.6 (A) (n) 1886 38.4 – – – n/ab Y N Y
A 11.4 (G) -> 11.8 (A) (n) 1.3 – 47.3c – – n/ab Y N Y
IL19 S1.4/ rs2243187 / NM_013371: c.364-1G>A A 4.7 (G) -> -6.2 (A) (n) 26.3 1.8d 1.8d 2.1d – n/ab Y Y N
C21orf2 S1.1/ rs2070573 / NM_004928: c.643-137A>C D 0.4 (A) -> 4.0 (C) (c) 12.1 NC 22.6 – – n/ab Y Y Y
TTC3 S1.21/ rs2835655 / NM_003316: c.5115G>A D 11.2 (G) -> 8.2 (A) (n) 8.1 1.5 – 1.3e – 1.5 – N N
TTC3f S1.5/ rs2835585 / NM_003316: c.188-8T>A A 7.6 (T) -> 5.4 (A) (n) 4.5 NC – 8.8 – n/ab Y N Y
WBP2NL S1.13/ rs17002806 / NM_152613: c.*86G>A D 9.2 (G) -> 6.0 (A) (n) 9.1 23.8 34+g – – n/ab N Y N
GUSBP11 S1.8/ rs3747107 / NR_024448: n.2961+6512
C>G
A 4.7 (C) -> -7.0 (G) (n) 25.9 98.3 31/
42.8h
– 1.6 n/ab Y/Ni N N
PRAMEj S1.9/ rs2266988k / NM_006115: c.19G>A D 7.8 (G) -> 6.2 (A) (n) 3.0 NC – 8.8 – n/ab N N N
PRAMEj S1.14/ rs2072049 / NM_006115: c.954-16G>T A 8.2 (G) -> 7.1 (T) (n) 2.2 2.6d – – – 3.1d - Y Y
UBASH3A S1.10/ rs1893592 /
NM_018961: c.1393+3A>C
D 8.7 (A) -> 4.2 (C) (n) 22.9 3.0 2.0/1.7l N/Am – 1.4 Y N Y
DERL3 S1.15/ rs6003906 / NM_198440: c.328-8A>T A –2.1 (A) -> -4.3 (T) (n) 4.6 NC 2.0 – – n/ab N Y N
ARFGAP3 S1.3/ rs1018448 / NM_014570: c.1065C>A A 10.5 (C) -> 8.3 (A) (n) 4.5 2.2 – 1.4 – 2.0 Y Y N
CFLAR S1.2/ rs10190751 / NM_003879: c.606
+934G>A NM_001127184:c.607-1G>A
A 16.1 (G) -> 5.2 (A) (n) 1885 10000+ – – 2.1 n/ab Y Y Y
IFI44L S1.11/ rs1333973 / NM_006820: c.478+3A>T D 9.1 (A) -> 4.6 (T) (n) 22.6 15.4 – 15.6 – 3.9 N Y N
LPP S1.12/ rs13076750 / NM_001167671:c.-66-
8G>A
A 9.3 (G) -> -1.6 (A) (n) 625 5000+ 15.8 26.6 – – Y N Y
EMID1 S1.7/ rs743920 / NM_133455: c.326C>G A 6.0 (C) -> 7.9 (G) (c) 3.6 n/ab 5.8 – – n/ab – Y N
CLDN14 S1.22/ rs16994182 / NM_001146078:c.-82
+4C>G
D 7.4 (C) -> 6.8 (G) (n) 1.6 5.9 – 2.1 – n/ab Y N/A N
BCR S1.17/ rs16802 / NM_004327:c.2708-13A>G A 5.6 (A) -> 5.8 (G) (n) 1.1 NCn – – – n/ab – N N
TMPRSS3 S1.19 / rs8130564 / NM_032404: c.66-13T>C A 4.2 (T) -> 4.4 (C) (n) 1.1 NCn – – – n/ab – N N
BACE2 S1.18/ rs2252576 / NM_012105: c.748-10C>T A 7.2 (C) -> 8.0 (T) (n) 1.5 NCn – – – n/ab – N N
CYB5R3 S1.20/ rs2285141 / NM_007326: c.-48-18G>T A 2.0 (G) -> 1.2 (T) (n) 1.7 NC – – 1.8 n/ab – N N
FAM3B S1.16/ rs2838010 / NM_058186: c.20-217A>T D –10.8 (A) -> 7.8 (T) (c) 228 – – – N/Ai n/ab Y N N
Red text indicates a decrease in the abundance of a particular splice form, while green text indicates an increase in abundance. A – Acceptor Splice Site Affected; D –Donor Splice Site Affected; NC - Not detectable (abolished). a Splicing events
which alter reading frame may induce nonsense-mediated decay; b No allele specific difference in expression and splicing; c complete discrimination of both isoforms using a custom designed TaqMan probe; d Values from comparing
heterozygote with homozygote common; e Change in splicing likely related to change in RNA level; f Intron 2-3 retention of TTC3 amplified by PCR, but no allele specific change detected; g This splice form not at detectable levels in
homozygote; h Cryptic acceptor 114nt upstream of affected site / cryptic acceptor 118nt upstream of affected site; i mRNA in-frame when alternate exon is used, and out of frame due to cryptic site use; j PRAME is a special case where two
SNPs affect splicing of two separate exons; k rs2266988 and rs1129172 are identical SNPs on opposite strands; l Cryptic donor 555nt downstream of affected site / cryptic donor 29nt downstream of affected site; m Splice form not detected
by PCR; n High variability between individuals with the same genotype by q-RT-PCR.
M
ucakiet
al.
C
on
firm
ing
P
redicted
A
llele-S
pecific
m
R
N
A
S
plicing
Frontiers
in
G
enetics
|
w
w
w
.frontiersin.org
M
arch
2020
|
Volum
e
11
|
A
rticle
109
8
SNP-Directed Effects on mRNA Levels
A change in the strength of a natural site of an exon can affect the
quantity of the processed mRNA (Caminsky et al., 2014). This
decrease in mRNA could be caused by nonsense mediated decay
(NMD), which degrades aberrant transcripts that would result in
premature protein truncation (Cartegni et al., 2002). Of the 22
SNPs tested, 2 showed a direct correlation between a decrease in
natural splice site strength, reduced amplification of the internal
reference by q-RT-PCR (of multiple individuals) and a
decreasing trend in expression by genotype by microarray:
rs2072049 (Supplementary Image 1.9) and rs1018448
(Supplementary Image 1.3), although these differences do not
meet statistical significance.
SNPs With Pertinent Splicing Effects
Detected by RNAseq
Evidence for impact on splicing of the previously described SNPs
was also assessed in TCGA and ICGC tumors by high
throughput expression analyses. Splicing effects of these
variants detected by q-RT-PCR and RNAseq were concordant
in 80% of cases (N = 16 of 20 SNPs), while impacts of 10% of
SNPs (N = 2) were partially concordant as a result of inconsistent
activation of cryptic splice sites (Supplementary Images 1.8D
and 1.10D). Several isoforms predicted by information analysis
of these SNPs were present in complete transcriptomes, but were
undetectable by q-RT-PCR or expression microarrays. Examples
include a 4.9 bit cryptic site activated by rs3747107 located 2
nucleotides from the natural splice site (Supplementary Image
1.8D), exon skipping by rs1893592 (Supplementary Image
1.10D), and a cryptic exon activated by rs2838010
(Supplementary Image 1.16C). Processed mRNAs that were
not detected by q-RT-PCR may have arisen as a result of a lack of
sensitivity of the assay, to NMD (which could mask detection of
mis-splicing), to a deficiency of an undefined trans-acting
splicing factor, or to design limitations in the experimental
design. Another possibility is that the discordant splicing
patterns of these two SNPs based could potentially be related
to differences in tissue origin, since only the RNAseq findings
were tumor-derived, whereas results obtained by the other
approaches were generated from RNA extracted from
lymphoblastoid cell lines. Cell culture conditions such as cell
density and phosphorylation status can affect alternative splicing
patterns (Li et al., 2006; Szafranski et al., 2014). These conditions,
however, have not been studied in cases of allele-specific,
sequence differences at splice sites or cis-acting regulatory sites
that impact splice site selection. Considering the high level of
concordance of splicing effects for the same SNPs in uncultured
and cultured cells, it seems unlikely that culture conditions
significantly impacts the majority of allele-specific, alternatively
spliced isoforms. Our information theory-based analyses show
that the dominant effect of SNP genotypes is to dictate common
changes in splice site strength regardless of cell origin.
The results obtained from q-RT-PCR and RNAseq data for
rs2070573, rs10190751, rs13076750, rs2072049, rs2835585,
TABLE 2 | Abundance of mRNA splice forms relative to internal gene reference.
Gene rsID mRNA Splice Form Homozygotes strong
allele (%)
[# Patients Tested]
Homozygotes weak
allele (%)
[# Patients Tested]
C21orf2 rs2070573 Extended Exon 6 Splice Form 45.3 ± 16.9 [2]1 1.5 ± 0.2 [2]
TTC3 rs2835585 Exon 3 Skipping <0.1 ± 0.0 [2] 0.3 ± 0.1 [2]
IL192 rs2243187 3 nt Inclusion of Exon 5 ~100 [1] 53.2 ± 3.0 [1; Het.]
IL192 rs2243187 3 nt Exclusion of Exon 5 61.0 ± 3.4 [1] ~100 [1; Het.]
IL192 rs2243187 Exon 5 Skipping 14.1 ± 1.4 [1] 6.8 ± 1.1 [1; Het.]
UBASH3A rs1893592 29 nt Retention of Intron 10 8.6 ± 4.6 [1] 4.2 ± 5.8 [1]
XRCC4 rs1805377 6 nt Inclusion of Exon 8 ~100 [1] 3.1 ± 0.5 [1]
XRCC4 rs1805377 6 nt Exclusion of Exon 8 2.6 ± 1.1 [1] 61.4 ± 26.3 [1]
PRAME rs2266988 Normal Exon 3 Splicing 32.4 ± 3.6 [1] 20.1 ± 3.9 [1]
PRAME rs2266988 Exon 3 Skipping 1.2 ± 1.2 [1] 3.5 ± 3.0 [1]
GUSBP11 rs3747107 Exon 8 Splicing 34.0 ± 0.6 [1] 0.3 ± 0.0 [2]
GUSBP11 rs3747107 Alternative Exon 8 37.3 ± 7.3 [1] 39.8 ± 3.7 [2]
GUSBP11 rs3747107 114 nt Retention of Intron 7 0.1 ± 0.0 [1] 1.4 ± 0.1 [2]
GUSBP11 rs3747107 118 nt Retention of Intron 7 0.2 ± 0.0 [1] 8.0 ± 0.5 [2]
DERL3 rs6003906 Normal Exon 5 Splicing ~100 [1] 55.8 ± 0.0 [1]
DERL3 rs6003906 Extended Exon 4; Short Exon 5 3.2 ± 0.0 [1] 4.0 ± 0.0 [1]
ARFGAP3 rs1018448 Exon 12 Skipping 12.3 ± 5.7 [3] 23.1 ± 10.1 [1]
IFI44L rs1333973 Normal Exon 2 Splicing 57.0 ± 0.0 [1] 14.7 ± 0.0 [1]
IFI44L rs1333973 Exon 2 Skipping 0.8 ± 0.0 [1] 48.0 ± 0.0 [1]
CFLAR rs10190751 Upstream Exon 7 Use ~100 [1] <0.1 ± 0.0 [1]
CFLAR rs10190751 Downstream Exon 7 Use 39.0 ± 0.0 [1] 87.1 ± 0.0 [1]
WBP2NL rs17002806 25 nt Intron 6 Retention N.D.2 2.3 ± 0.0 [1]
CYB5R3 rs2285141 Alternate Exon 2 Use <0.1 ± 0.0 [1] <0.1 ± 0.0 [1]
EMID1 rs743920 6 nt deletion of Exon 4 69.0 ± 9.7 [1] 9.2 ± 1.4 [1]
CLDN14 rs16994182 Exon 2 Skipping 1.9 ± 0.0 [1] 5.3 ± 0.0 [1]
1Average expression was computed by comparing qPCR Ct values across multiple experimental runs and normalized against Ct of internal gene reference. SNPs tested in multiple
experiments with one individual of each genotype will have a standard deviation of 0.0. 2Heterozygote; Individuals who are homozygous for IL19 SNP rs2243187 were not available for
testing. N.D., Not detected. Ct values were not available for LPP rs13076750.
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rs1893592, and rs1805377 were complementary to findings
based on RNAseq (Supplementary Table 2). RNAseq data can
reveal potential allele-specific alternate splicing events that were
not considered at the primer design phase of the study, while q-
RT-PCR is more sensitive and can reveal less abundant
alternative splice forms. A weak 0.4 bit splice site associated
with rs2070573 was less abundant than the extended isoform
(Figure 2) by both q-RT-PCR and exon microarray, however
ValidSpliceMut also revealed increased total C21orf2 intron 6
retention in five tumors with this allele. Similarly, rs10190751
was flagged for intron retention in 29 tumors, which was not
evident by the other approaches. The long form of this transcript
(c-FLIP[L]) in homozygous carriers of this SNP was twice as
abundant by q-RT-PCR than the shorter allele, associated with
the weak splice site. rs13076750 activates an alternate acceptor
site for a rare exon that extends the original exon length by seven
nucleotides. The exon boundary can also extend into an adjacent
exon, based on RNAseq of eight tumors carrying this SNP.
Expression was decreased in the presence of a 6.2 bit splice site
derived from a rs2072049 allele that weakens the natural
acceptor site of the terminal exon of PRAME. The actual cause
of diminished expression is likely to have been related to NMD
from intron retention. ValidSpliceMut showed intron retention
to be increased in rs2835585, whereas increased exon skipping
for the allele with the weaker splice site was demonstrated by q-
RT-PCR. rs1893592 caused significant intron retention in all
tumors (N = 9), with exon skipping present in 3 diffuse large B-
cell lymphoma patients, which was not detected by q-RT-PCR.
Finally, rs1805377 was associated with the significant abundance
of read sequences indicating XRCC4 intron 7 retention by
RNAseq (N = 32), however this isoform could not be
distinguished by the primers designed for q-RT-PCR and by
TaqMan assay.
Alternative splicing events detected by RNAseq that were not
evident in either q-RT-PCR or microarray studies included exon
skipping induced by rs743920 (Supplementary Image 1.7D),
activation of a preexisting cryptic splice site by rs1333973
(Figure 3), and intron retention by rs6003906 (Supplementary
Image 1.15D). rs743920 creates an exonic hnRNP A1 site (Ri =
2.8 bits) distant from the natural site which may compromise
exon definition (Mucaki et al., 2013; Peterlongo et al., 2015) and
may explain the SNP-associated increase in exon skipping. Exon
definition analyses of total exon information (Ri,total) also
predicted the cryptic isoform arising from rs1333973 to be the
most abundant (Ri,total = 9.4 bits).
Allele-Specific mRNA Splicing for Other
SNPs Identified Through RNAseq
A distinct set of 24 high population frequency SNPs were also
evaluated for their potential impact on mRNA splicing by
RNAseq analysis of ICGC patients. Those resulting in
significantly decreased natural splice site strength (DRi < −1
bit) were analyzed for SNP-derived alternative splicing events.
SNPs fulfilling these criteria expressed at sufficient levels over the
region of interest were: rs6467, rs36135, rs154290, rs166062,
rs171632, rs232790, rs246391, rs324137, rs324726, rs448580,
TABLE 3 | RNAseq analysis of natural splice sites weakened by common single nucleotide polymorphisms (SNPs).
Gene rsID1 HGVS Notation
(HG19)2
Ri initial Ri final DRi Alternative Splicing Observed
CYP21A2 rs6467 6:32006858C > A 6.1 4.5 −1.6 Intron Retention; Cryptic Site Use
TRIM23 rs36135 5:64890479A > C 10.0 7.5 −2.5 Intron Retention
ZFYVE16 rs166062 5:79773028T > G 14.1 11.8 −2.4 Intron Retention
APBB3 rs171632 5:139941318A > G 2.5 1.4 −1.1 Intron Retention; Cryptic Site Use
SMIM8 rs448580 6:88040399T > G 6.9 4.4 −2.5 Exon Skipping
FCHSD1 rs469074 5:141024136T > G 10.4 7.1 −3.3 Intron Retention
KIFAP3 rs518928 1:169890933A > G 15.6 14.5 −1.1 Intron Retention
CEPT1 rs694180 1:111726213A > G 9.6 7.0 −2.6 Intron Retention
ADCY10P1 rs722442 6:41089681A > G 7.5 4.9 −2.5 Exon Skipping
MICAL1 rs752262 6:109770999G > C 4.0 2.7 −1.4 Intron Retention
MAP3K1 rs832567 5:56152416C > A 6.8 5.0 −1.7 Intron Retention; Exon Skipping
METTL13 rs909958 1:171763522C > A 11.4 9.9 −1.4 Intron Retention
DDX39B rs933208 6:31506648G > T 4.8 3.7 −1.1 Intron Retention; Cryptic Site Use
CCT7 rs1018342 2:73471653T > G 5.9 4.4 −1.5 Intron Retention
PPIP5K2 rs154290 5:102537200T > G 12.5 11.3 −1.3 Wildtype Only
MYSM1 rs232790 1:59131311G > T 10.4 8.7 −1.7 Wildtype Only
PDGFRB rs246391 5:149497177T > C 6.2 3.6 −2.6 Wildtype Only
AARS2 rs324137 6:44273546A > C 10.2 8.9 −1.3 Wildtype Only
USO1 rs324726 4:76722353G > A 11.8 8.8 −3.0 Wildtype Only
KIF13A rs624105 6:17855864G > C 14.1 13.0 −1.1 Wildtype Only
TNFRSF1B rs653667 1:12251808T > G 3.7 2.4 −1.3 Wildtype Only
CCDC93 rs748767 2:118731573G > A 4.6 3.4 −1.1 Wildtype Only
CAPN2 rs751128 1:223951841T > C 5.3 4.2 −1.1 Wildtype Only
FYCO1 rs751552 3:46016851A > T 6.9 4.7 −2.2 Wildtype Only
1rsIDs are hyperlinked to their associated dbSNP page; 2If present, variant coordinates are hyperlinked to the ValidSpliceMut database; Thick bars separate SNP-affected exons with and
without RNAseq-observed alternate splicing events.
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rs469074, rs518928, rs624105, rs653667, rs694180, rs722442,
rs748767, rs751128, rs751552, rs752262, rs832567, rs909958,
rs933208, and rs1018342 (Table 3). Splicing was predicted to
be leaky for all natural splice sites affected by these SNPs (Rogan
et al., 1998; Ri,final ≥ 1.6 bits), where reduction in Ri values ranged
from 1.1 to 3.3 bits.
Alternative mRNA splicing was observed in 14 SNPs: rs6467,
rs36135, rs166062, rs171632, rs448580, rs469074, rs518928,
rs694180, rs722442, rs752262, rs832567, rs909958, rs933208,
rs1018342; Table 3). Reads spanning these regions revealed
intron retention (N = 12), activation of cryptic splicing
(N = 4), and complete exon skipping (N = 3). Eleven of these
SNPs (79%) exhibited splicing patterns that significantly differed
from the control alleles, and were therefore present in
ValidSpliceMut. Interestingly, ValidSpliceMut contained
entries for 7 of 10 SNPs where alternative splicing had not
been found in the two patients reported in Table 3 (rs246391,
rs324137, rs624105, rs653667, rs748767, rs751128, rs751552).
The observed significant splicing differences for these SNPs
occurred in distinct tumor types, consistent with tissue-specific
effects of these SNPs on splicing.
Instances of Limited Corroboration of
SNP-Related Predictions
Anticipated effects of the SNPs on splicing were not always
confirmed by expression studies. Aside from incomplete or
incorrect predictions, both design and execution of these
studies as well as uncharacterized tissue specific effects could
provide an explanation for these discrepancies. Furthermore,
these undetected splicing events may have been targeted for
NMD, however expression was not compared with mRNA levels
from cells cultured with an inhibitor of protein translation.
Stronger preexisting cryptic sites were, in some instances, not
recognized nor was isoform abundance changed. These include:
rs1893592 (6.4 and 5.2 bit cryptic donor sites 29 and 555 nt
downstream of the affected donor); rs17002806 (a 5.7 bit site 67
nt downstream of the natural site); rs3747107 [creates a 4.9 bit
cryptic site 2 nt downstream (observed by RNAseq;
Supplementary Image 1.8 D)]; and rs2835585 (5.8 and 5.9 bit
cryptic sites 60 and 87 nt upstream of the natural site). SNPs with
modestly decreased natural site strength (0.2 to 4.5 bits) did not
consistently result in exon skipping (for example, rs1893592,
rs17002806, and rs2835655).
Six SNPs predicted to disrupt natural splice sites could not be
confirmed. Splicing effects were not identified in the 4 SNPs
where the information change was < 1 bit (<twofold). Genetic
variability masked potential splicing effects of three of these
SNPs, including rs16802, rs2252576, and rs8130564 (Table 1).
PCR primer sets designed for COL6A2 exon 21 (affected by
rs17357592) did not produce the expected amplicon.
Interpreting the results for rs16994182 (CLDN14) was
complicated by the lack of a suitable internal reference. As
CLDN14 consists of three exons, any internal reference
covering the affected second exon cannot parse whether
differences in exon 2 expression were caused by the SNP or by
general expression changes.
The T-allele rs2838010 was predicted to activate a donor
splice site of a rare exon in IVS1 of FAM3B (GenBank Accession
AJ409094). The cryptic pseudoexon was neither detected by
RT-PCR nor expression microarray (Supplementary Image
1.16). Interestingly, this exon is expressed in a malignant
lymphoma patient who is a carrier for this genotype [ICGC
ID: DO27769; (Supplementary Image 1.16C)]. Although the T-
allele is probably required to activate the pseudoexon, additional
unknown splicing-related factors appear to be necessary.
DISCUSSION
Predicted SNP alleles that alter constitutive mRNA splicing are
confirmed by expression data, and appear to be a common cause
of alternative splicing. The preponderance of leaky splicing
mutations and cryptic splice sites, which often produce both
normal and mutant transcripts, is consistent with balancing
selection (Nuzhdin et al., 2004) or possibly with mutant loci
that contribute to multifactorial disease. Minor SNP alleles are
often found in > 1% of populations (Janosíková et al., 2005). This
would be consistent with a bias against finding mutations that
abolish splice site recognition in dbSNP. Such mutations are
more typical in rare Mendelian disorders (Rogan et al., 1998).
Exon-based expression microarrays and q-RT-PCR techniques
were initially used to confirm the predicted impact of common
and rare SNPs on splicing. Results were subsequently confirmed
using RNAseq data for some of these SNPs (Dorman et al., 2014;
Viner et al., 2014; Shirley et al., 2019). However, exon skipping due
to rs1893592 was not consistently seen in all carriers. Although
detected only in one type of tumor, this event may not be tissue
specific, since five patients with the same genotype did not exhibit
this isoform. Nevertheless, exon skipping was also observed in
malignant lymphoma (Supplementary Image 1.10D). Intron
retention in rs1805377 carriers was evident in only 22% of
tumors. Increased total intron retention may be due to failure to
recognize exons due to overlapping strong splice sites (Vockley
et al., 2000; Rogan et al., 2003).
The splicing impacts of several of these SNPs have also been
implicated in other studies. rs10190751 modulates the FLICE-
inhibitory protein (c-FLIP) from its S-form to its R-form, with the
latter having been linked to increased lymphoma risk (Ueffing
et al., 2009). We observed the R-form to be twice as abundant for
one of the rs10190751 alleles. Increased exon skipping attributed
to rs1333973 has been reported in RNAseq analysis of IFI44L
(Zhao et al., 2013a), which has been implicated in reduced
antibody response to measles vaccine (Haralambieva et al.,
2017). The splicing impact of XRCC4 rs1805377 has been noted
previously (Nalla and Rogan, 2005). This SNP has been implicated
with an increased risk of gastric cancer (Chiu et al., 2008),
pancreatic cancer (Ding and Li, 2015) and glioma (Zhao et al.,
2013b). Similarly, the potential impact of rs1893592 in UBASH3A
has been recognized (Kim et al., 2015) and is associated with
arthritis (Liu et al., 2017) and type 1 diabetes (Ge and Concannon,
2018). Hiller et al. (2006) described the 3nt deletion caused by
rs2243187 in IL19 but did not report increased exon skipping.
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rs743920 was associated with change in EMID1 expression (Ge
et al., 2005), however its splicing impact was not recognized.
Conversely, studies linking TMPRSS3 variants to hearing loss did
not report rs8130564 to be significant (Lee et al., 2013; Chung
et al., 2014). Interestingly, rs2252576 (in which we did not find a
splicing alteration) has been associated to Alzheimer’s dementia in
Down syndrome (Mok et al., 2014).
rs2835585 significantly increased exon skipping in TTC3,
however normal expression levels at the affected exon junction
were not significantly altered. This was most likely due to the
large difference in abundance between the constitutive and
skipped splice isoforms (Table 2). The skipped isoform does
not disrupt the reading frame and the affected coding region has
not been assigned to any known protein domain (Tsukahara
et al., 1996; Suizu et al., 2009). It is unclear whether allele-specific,
exon skipping in this instance would impact TTC3 protein
function or activity.
Why are so few natural splice sites strengthened by SNP-induced
information changes? Most such changes would be thought to be
neutral mutations, which are ultimately lost by chance (Fisher,
1930). Those variants which are retained are more likely to confer a
selective advantage (Li, 1967). Indeed, the minor allele in rs2266988,
which strengthens a donor splice site by 1.6 bits at the 5' end of the
open reading frame in PRAME and occurs in 25% of the overall
population (~50% in Europeans). Several instances of modest
changes in splice site strength that would be expected to have
little or no impact, in fact, alter the degree of exon skipping.
Allele frequency can significantly vary across different
populations, which can be indicative of gene flow and migration
of a population (Cavalli-Sforza and Bodmer, 1971) as well as, in the
case of splicing variants, genetic load and fitness in a population
(Rogan and Mucaki, 2011). The frequencies of several of the
variants presented here are significantly different between ethnic
and geographically defined populations (Tables 1 and 3). We
examined allele frequencies of these variants in sub-populations in
both HapMap and dbSNP version 153. For example, representation
of the alleles of the XRCC4 variant rs1805377 (where its A-allele
leads to a 6 nt deletion of the gene's terminal exon) differs between
Caucasians and Asians (for the G- and A-alleles, respectively).
Different linkage disequilibrium patterns of this variant occur in
Han Chinese (CHB) and Utah residents with Northern and
Western European ancestry (CEU) populations (Zhao et al.,
2013b). Similar differences in SNP population frequency include
EMID1 rs743920 (in HapMap: G-allele frequency is 47% in CHB,
but only 7% in CEU and 10% in northern Swedish cohorts). This is
consistent with dbSNP (version 153) where it is present in 72% in
Vietnamese, but only 16% of a northern Sweden cohort). In BACE2,
rs2252576, the T-allele is most prevalent at 84% in Yoruba in
Ibadan, Nigeria populations (YRI), but only 8% in CHB. In
FCHSD1, rs469074 the frequency of the G-allele is 37% in YRI
and <1% in CHB. Some SNPs were exclusively present in a single
population in the HapMap cohort (e.g. only the YRI population is
polymorphic for IL19 rs2243187, WBP2NL rs17002806, DERL3
rs6003906, and CLDN14 rs16994182).
Because of their effects onmRNA splicing, these differences in allele
frequency would be expected to alter the relative abundance of certain
protein isoforms in these populations. We speculate about whether
isoform-specific representation among populations influences disease
predisposition, other common phenotypic differences, or whether they
are neutral.We suggest that SNPs decreasing constitutive splicing while
increasing mRNA isoforms which alter the reading frame would be
more likely to result in a distinct phenotype. q-RT-PCR experiments
confirmed five SNPs which increased the fraction of mRNA splice
forms causing a frameshift (Table 1), three of which simultaneously
decrease constitutive splicing by ≥ 10-fold (WBP2NL rs17002806;
GUSBP11 rs3747107; and IFI44L rs1333973). rs3747107 and
rs17002806 are much more common in YRI populations in
HapMap (rs3747107 G-allele is present in 64% in YRI but only
23% in CEU; rs17002806 A-allele was not identified in any CHB or
CEU individuals), while the A-allele of rs1333973 is much more
common inCHB (76%, compared to 31%and35% inCEUandYRI
populations, respectively). These common variants are likely to
change the function of these proteins andmay influence individual
phenotypes. A somewhat comprehensive catalog of DNA
polymorphisms with splicing effects—confined or with increased
prevalence in specific ethnic or geographically identifiable groups—
could be derived fromcombiningValidSpliceMutwith population-
specific SNP databases. Aside from those phenotypes described
earlier, genes implicated by GWAS or other analyses for specific
disorders represent reasonable candidates for further detailed or
replication studies aimed at identification of the risk alleles in
these cohorts.
The extent to which SNP-related sequence variation
accounts for the heterogeneity in mRNA transcript
structures has been somewhat unappreciated, given the
relatively high proportion of genes that exhibit tissue-
specific alternative splicing (Pan et al., 2008; Wang et al.,
2008; Baralle and Giudice, 2017). This and our previous study
(Shirley et al., 2019) raise questions regarding the degree to
which apparent alternative splicing is the result of genomic
polymorphism rather than splicing regulation alone. Because
much of the information required for splice site recognition
resides within neighboring introns, it would be prudent to
cons ider cont r ibut ions f rom int ron ic and exonic
polymorphism that produce structural mRNA variation,
since these changes might be associated with disease
or predisposition.
Individual information corresponds to a continuous
molecular phenotypic measure that is well suited to the
analysis of contributions of multiple, incompletely penetrant
SNPs in different genes, as typically seen in genetically
complex diseases (Cooper et al., 2013). Our protocol
identifies low or nonpenetrant allele-specific alternative
splicing events through bioinformatic analysis, and either q-
RT-PCR, exon microarrays or RNAseq data analysis. Allele-
specific splicing can also be determined by full-length
alternative isoform analysis of RNA [or FLAIR (Workman
et al., 2019)]. Differentiated splice forms are associated with
specific alleles in heterozygotes with exonic SNPs. However,
combining genome-based information with FLAIR may
enable identification of intronic SNPs influencing splicing
and low abundance alternative splice forms, which might
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otherwise be missed by FLAIR.
Targeted splicing analysis generally reproduces the results of our
multi- genome-wide surveys of sequence variations affectingmRNA
splicing. As splicing mutations and their effects were often observed
in multiple tumor types, the impact of these mutations may be
pleiotropic. Some events were only detected in q-RT-PCR data and
not by RNAseq (and vice versa), highlighting the complementarity
of these techniques for splicing mutation analyses. Results of this
study increase confidence that the publicly (https://ValidSpliceMut.
cytognomix.com) and commercially (https://MutationForecaster.
com) available resources for information-theory based variant
analysis and validation can distinguish mutations contributing to
aberrant molecular phenotypes from allele-specific alternative splicing.
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